🇺🇸 FDA

Intelligence · Clinical Pipeline

George Institute for Pipeline

All ClinicalTrials.gov programs at George Institute for — phase, modality, and trial IDs.

Programs
83

Quick answer

George Institute for has 83 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. LIVTENCITY 200 mg film-coated tablets.

    The George Institute

    Transplant patients with high recurrent Epstein-Barr infection

    approved small molecule active

    1 trial

  2. Levobupivacaína Normon 5 mg/ml solución inyectable y para perfusión EFG, Inibsacain 5 mg/ml + 0,005 mg/ml solución inyectable en cartucho

    The George Institute

    Hip fracture

    approved small molecule active

    1 trial

  3. Lixiana 30 mg film-coated tablets, Lixiana 60 mg film-coated tablets

    The George Institute

    High risk atrial fibrillation patients with previous intracranial hemorrhage

    approved small molecule active

    1 trial

  4. Metformin Actavis 500 mg filmdragerad tablett

    The George Institute

    Polycystic ovary syndrome

    approved small molecule active

    1 trial

  5. Microcrystalline cellulose, GABAPENTINE BIOGARAN 300 mg, gélule

    The George Institute

    lumbosacral radiculalgia

    approved small molecule active

    1 trial

  6. Mounjaro 5 mg solution for injection in pre-filled pen, Mounjaro 2.5 mg solution for injection in pre-filled pen

    The George Institute

    Obesity

    approved small molecule active

    1 trial

  7. Norfloxacino Sandoz 400 mg comprimidos EFG

    The George Institute

    Hospitalized patients with decompensated cirrhosis, diagnosed with bacterial infection evolution lasting for 48 hours or less.

    approved small molecule active

    1 trial

  8. OPDIVO 10 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets

    The George Institute

    Renal carcinoma

    approved small molecule active

    1 trial

  9. ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, RoActemra 162 mg solution for injection in pre-filled syringe., ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, RoActemra 162 mg solution for injection in pre-filled syringe., ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg sol

    The George Institute

    Adults patients suffering from rheumatoid arthritis and in adequate response to one or two targeted treatments.

    approved small molecule active

    1 trial

  10. Ozempic 1 mg solution for injection in pre-filled pen, Dapagliflozin 10 mg film-coated tablets

    The George Institute

    Type 2 diabetes

    approved small molecule active

    1 trial

  11. Pentocur 1 g pulver till injektionsvätska, lösning

    The George Institute

    Major depressive disorder

    approved small molecule active

    1 trial

  12. Plasma rich in growth factors, -

    The George Institute

    Glaucoma, Dry eye disease

    approved small molecule active

    1 trial

  13. Prednisona Pensa 5 mg comprimidos EFG, Simulect 20 mg powder for solution for injection or infusion, tacrolimus cinfa 1 mg cápsulas duras EFG, Micofenolato Mofetile Accord 250 mg capsule rigide, Metilprednisolona NORMON 40 mg polvo y disolvente para solución inyectable EFG, TIMOGLOBULINA 5 mg/ml, polvo para solución para perfusión

    The George Institute

    Kidney Transplant

    approved small molecule active

    1 trial

  14. RIBOCICLIB, Kisqali 200 mg film-coated tablets

    The George Institute

    Hormone receptor–positive (HRpos)/human epidermal growth factor receptor 2–negative (HER2neg) early breast cancer at risk of recurrence

    approved small molecule active

    1 trial

  15. ROSUVASTATIN AND EZETIMIBE , BEMPEDOIC ACID , ROSUVASTATIN AND EZETIMIBE , ATORVASTATIN AND AMLODIPINE

    The George Institute

    CHRONIC INFLAMMATORY RHEUMATIC DISEASE: rheumatoid arthritis or psoriatic arthritis or axial spondyloarthritis or systemic lupus erythematosus

    approved small molecule active

    1 trial

  16. Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze Tollwut-Impfstoff (inaktiviert), RABIPUR, poudre et solvant pour solution injectable en seringue préremplie. Vaccin rabique (inactivé)., Rabipur poeder en oplosmiddel voor oplossing voor injectie in een voorgevulde spuit.Rabiësvaccin (geïnactiveerd).

    The George Institute

    rabies pre-exposure prophylaxis

    approved small molecule active

    1 trial

  17. Rapamune 1 mg coated tablets, MYCOPHENOLATE MOFETIL

    The George Institute

    End-stage kidney disease in Type 1 diabetes, SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA

    approved small molecule active

    1 trial

  18. Recigarum 1,5 mg comprimidos recubiertos con película EFG

    The George Institute

    Active smokers

    approved small molecule active

    1 trial

  19. Rifaldin 300 mg cápsulas, Rimactán 300 mg cápsulas duras, Cemidón 300 B6, RIFAPENTINE

    The George Institute

    Latent tuberculosis infection in patients with end-stage kidney disease.

    approved small molecule active

    1 trial

  20. Ropivacaine B. Braun 10 mg/ml injektionsvätska, lösning

    The George Institute

    lumbar arthrodesis

    approved small molecule active

    1 trial

  21. SILDENAFIL , LEVOTHYROXINE SODIUM

    The George Institute

    erectile function, hypothyroidism subclinic

    approved small molecule active

    1 trial

  22. SINECATECHINS

    The George Institute

    Anal high-grade squamous intraepithelial lesions (HSIL).

    approved small molecule active

    1 trial

  23. SUMATRIPTAN , GLYCERYL TRINITRATE , RIMEGEPANT

    The George Institute

    Migraine

    approved small molecule active

    1 trial

  24. Sitagliptin 50mg Film-coated Tablets, Trajenta 5 mg film-coated tablets, Pioglitazone Mylan 15 mg compresse, Ozempic 0.5 mg solution for injection in pre-filled pen, Jardiance 10 mg film-coated tablets, GLUCOPHAGE 1000 mg potahované tablety, Invokana 100 mg film-coated tablets, Trulicity 1.5 mg solution for injection in pre-filled pen, Galvus 50 mg tablets, Forxiga 10 mg film-coated tablets

    The George Institute

    Type 2 Diabetes Mellitus

    approved small molecule active

    1 trial

  25. Sulfato de Magnesio Altan 150 mg/ml solución inyectable y para perfusión EFG, LIDOCAINE HYDROCHLORIDE, Dexdor 100 micrograms/ml concentrate for solution for infusion, KETOLAR 50 mg/ml solución inyectable.

    The George Institute

    Obesity

    approved small molecule active

    1 trial

  26. TACROLIMUS, SIROLIMUS, MYCOPHENOLATE MOFETIL, AZATHIOPRINE, PREDNISOLONE, EVEROLIMUS, MYCOPHENOLIC ACID, BELATACEPT, CICLOSPORIN

    The George Institute

    BK Polyomavirus DNAemia after kidney transplantation

    approved small molecule active

    1 trial

  27. TESTOGEL 50 mg gel transdérmico en sobres, Decapeptyl diario 0,1 mg polvo y disolvente para solución inyectable, Bemfola 300 IU/0.50 mL solution for injection in pre-filled pen, Astarté 0,25 mg/0,5 ml solución inyectable en jeringa precargada EFG

    The George Institute

    low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism

    approved small molecule active

    1 trial

  28. TRANEXAMIC ACID

    The George Institute

    Hip fracture

    approved small molecule active

    1 trial

  29. Trangorex 200 mg comprimidos

    The George Institute

    Atrial fibrillation

    approved small molecule active

    1 trial

  30. Ultomiris 300 mg/30 mL concentrate for solution for infusion

    The George Institute

    IgA nephropathy

    approved small molecule active

    1 trial

  31. Urapidil Accord 5 mg/ml solución inyectable y para perfusión EFG, Trandate 5mg/ml Solution for Injection, Fenilefrina Altan 0,1 mg/ml solución inyectable y para perfusión.

    The George Institute

    Acute Ischemic Stroke

    approved small molecule active

    1 trial

  32. Vabysmo 120 mg/mL solution for injection in pre-filled syringe

    The George Institute

    SUBRETINAL HYPERREFLECTIVE MATERIAL

    approved small molecule active

    1 trial

  33. Vyvgart 20 mg/mL concentrate for solution for infusion

    The George Institute

    Patients affected by generalized myasthenia gravis

    approved small molecule active

    1 trial

  34. Wegovy 2.4 mg solution for injection in pre-filled pen

    The George Institute

    obstructive sleep apnea

    approved small molecule active

    1 trial

  35. Xtandi - 40 mg soft capsules

    The George Institute

    PROSTATE CANCER

    approved small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does George Institute for have?

83 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.